Sign in
Seema Sheoran

Seema Sheoran

Research Analyst at Evercore ISI

New York, NY, US

Seema Sheoran is an Equity Analyst at Evercore ISI, specializing in healthcare sector research with a focus on biotechnology and pharmaceutical companies. Sheoran has covered specific companies such as BioCryst Pharmaceuticals and Altimmune, frequently participating in their quarterly earnings calls and providing institutional equities research recognized for its depth and insight. Her career at Evercore ISI includes active involvement in industry events, though comprehensive public rankings and performance statistics have not been disclosed. While detailed licensing and prior firm affiliations are not listed in available public records, her ongoing analyst role and participation in major company coverage highlight her expertise in the life sciences space.

Seema Sheoran's questions to BIOCRYST PHARMACEUTICALS (BCRX) leadership

Question · Q4 2024

Seema Sheoran, on for Liisa Bayko, asked about the target product profile for avoralstat in diabetic macular edema (DME) and what investors should look for in the upcoming Phase 1 data.

Answer

Chief Commercial Officer Charlie Gayer outlined the target profile as an infrequent injection, potentially every 3-6 months, for the nearly 50% of DME patients who do not fully respond to anti-VEGF therapies. Chief R&D Officer Dr. Helen Thackray added that the Phase 1 trial will enroll patients directly to assess safety, tolerability, and initial signs of activity, such as changes in edema and visual acuity, after a single injection.

Ask follow-up questions

Fintool

Fintool can predict BIOCRYST PHARMACEUTICALS logo BCRX's earnings beat/miss a week before the call